Advertisement

Archivum Immunologiae et Therapiae Experimentalis

, Volume 65, Issue 6, pp 463–475 | Cite as

Evaluation of Endothelial Function by Flow-Mediated Dilation: a Comprehensive Review in Rheumatic Disease

  • Luca Moroni
  • Carlo Selmi
  • Claudio Angelini
  • Pier Luigi Meroni
Review

Abstract

Flow-mediated dilation (FMD) represents a non-invasive marker of endothelial function to evaluate vascular homeostasis, which reflects the effects of several mechanisms, including vessel tone regulation, cell proliferation, and inflammatory responses. Beyond classical atherosclerotic risk factors such as arterial hypertension, diabetes mellitus, smoking, obesity, and dyslipidemia, chronic inflammation contributes to the endothelial dysfunction causing plaque formation and there is growing evidence of a significantly higher cardiovascular morbidity associated with autoimmune diseases. The endothelium reacts to several endogenous and exogenous stimuli, through surface receptors and intracellular signalling, and releases numerous vasoactive substances, including endothelins, prostacyclins, and nitric oxide (NO). Chronic inflammatory rheumatic diseases are commonly associated with decreased endothelial NO production, vascular damage, and premature atherosclerosis. Despite partially eclipsed by pulse wave velocity measure in the modern scientific literature, we provide a comprehensive overview and critically discuss the available data supporting FMD as a surrogate marker of endothelial function and, therefore, its potential role in predicting early atherosclerosis in patients with rheumatic diseases.

Keywords

Cardiovascular risk Chronic inflammation Rheumatoid arthritis Psoriatic arthritis Connective tissue disease Autoantibody 

Abbreviations

APS

Anti-phospholipid syndrome

aPL

Anti-phospholipid antibodies

CVD

Cardiovascular disease

EDHF

Endothelium-derived hyperpolarizing factor

eNOS

Endothelial NO synthase

FMD

Flow-mediated dilation

MCTD

Mixed connective tissue disease

MTX

Methotrexate

NO

Nitric oxide

oxLDL

Oxidized low-density lipoproteins

PsA

Psoriatic arthritis

RA

Rheumatoid arthritis

SLE

Systemic lupus erythematosus

SpA

Spondyloarthropathies

SSc

Systemic sclerosis

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest in relation to the presented work.

References

  1. Akoglu H, Seringec N, Yildirim T et al (2013) Relationship between hemorheology and endothelial dysfunction in renal transplant patients receiving calcineurin inhibitors. J Nephrol 26:931–940PubMedCrossRefGoogle Scholar
  2. Altabas V, Altabas K, Kirigin L (2016) Endothelial progenitor cells (EPCs) in ageing and age-related diseases: How currently available treatment modalities affect EPC biology, atherosclerosis, and cardiovascular outcomes. Mech Ageing Dev 159:49–62PubMedCrossRefGoogle Scholar
  3. Arosio E, De Marchi S, Rigoni A et al (2007) Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 25:1273–1278PubMedCrossRefGoogle Scholar
  4. Astry B, Venkatesha SH, Moudgil KD (2013) Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis. Indian J Med Res 138:717–731PubMedPubMedCentralGoogle Scholar
  5. Barter PJ, Nicholls S, Rye KA et al (2004) Antiinflammatory properties of HDL. Circ Res 95:764–772PubMedCrossRefGoogle Scholar
  6. Ben-Shlomo Y, Spears M, Boustred C et al (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63:636–646PubMedCrossRefGoogle Scholar
  7. Bertoli AM, Alarcon GS, Calvo-Alen J et al (2006a) Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum 54:1580–1587PubMedCrossRefGoogle Scholar
  8. Bertoli AM, Fernandez M, McGwin G Jr et al (2006b) Association of antioxidized low-density lipoprotein antibodies with vascular arterial events and renal manifestations in systemic lupus erythematosus patients: comment on the article by Frostegard et al. Arthritis Rheum 54:2035–2036PubMedCrossRefGoogle Scholar
  9. Bilsborough W, Keen H, Taylor A et al (2006) Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26:1125–1131PubMedCrossRefGoogle Scholar
  10. Bosello S, Santoliquido A, Zoli A et al (2008) TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 27:833–839PubMedCrossRefGoogle Scholar
  11. Bots ML, Westerink J, Rabelink TJ et al (2005) Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 26:363–368PubMedCrossRefGoogle Scholar
  12. Brennan FM, Chantry D, Jackson A et al (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244–247PubMedCrossRefGoogle Scholar
  13. Brey RL, Abbott RD, Curb JD et al (2001) beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 32:1701–1706PubMedCrossRefGoogle Scholar
  14. Bruno RM, Bianchini E, Faita F et al (2014) Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound 12:34PubMedPubMedCentralCrossRefGoogle Scholar
  15. Capria A, De Nardo D, Baffetti FR et al (2010) Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 23:255–262PubMedCrossRefGoogle Scholar
  16. Celermajer DS (1997) Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 30:325–333PubMedCrossRefGoogle Scholar
  17. Celermajer DS, Sorensen KE, Gooch VM et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. The Lancet 340:1111–1115CrossRefGoogle Scholar
  18. Cerinic MM, Valentini G, Sorano GG et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285–295PubMedCrossRefGoogle Scholar
  19. Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027PubMedCrossRefGoogle Scholar
  20. Cervera R, Serrano R, Pons-Estel GJ et al (2015) Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74:1011–1018PubMedCrossRefGoogle Scholar
  21. Chatterjee Adhikari M, Guin A, Chakraborty S et al (2012) Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 41:669–675PubMedCrossRefGoogle Scholar
  22. Chin CW, Chin CY, Ng MX et al (2014) Endothelial function is associated with myocardial diastolic function in women with systemic lupus erythematosus. Rheumatol Int 34:1281–1285PubMedCrossRefGoogle Scholar
  23. Choi HK, Hernan MA, Seeger JD et al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177PubMedCrossRefGoogle Scholar
  24. Contessa C, Ramonda R, Lo Nigro A et al (2009) [Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data]. Reumatismo 61:298–305PubMedGoogle Scholar
  25. Conti F, Spinelli FR, Alessandri C et al (2014) Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on beta2GPI-specific T cell response. Arterioscler Thromb Vasc Biol 34:661–668PubMedCrossRefGoogle Scholar
  26. Corretti MC, Plotnick GD, Vogel RA (1995) Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol 268(4 Pt):H1397–H1404PubMedGoogle Scholar
  27. Corretti MC, Anderson TJ, Benjamin EJ et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265PubMedCrossRefGoogle Scholar
  28. Cugno M, Borghi MO, Lonati LM et al (2010) Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 34:105–110PubMedCrossRefGoogle Scholar
  29. Daiber A, Steven S, Weber A et al (2016) Targeting vascular (endothelial) dysfunction. Br J Pharmacol. doi: 10.1111/bph.13517 Google Scholar
  30. Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115:1285–1295PubMedGoogle Scholar
  31. del Rincon I, O’Leary DH, Haas RW et al (2004) Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 50:3813–3822PubMedCrossRefGoogle Scholar
  32. DeMaria AN (2002) Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 89:33D–38DPubMedCrossRefGoogle Scholar
  33. Dhawan V, Handu SS, Nain CK et al (2005) Chronic l-arginine supplementation improves endothelial cell vasoactive functions in hypercholesterolemic and atherosclerotic monkeys. Mol Cell Biochem 269:1–11PubMedCrossRefGoogle Scholar
  34. Di Minno MN, Ambrosino P, Lupoli R et al (2015) Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies. Ann Med 47:346–353PubMedCrossRefGoogle Scholar
  35. Domsic RT, Dezfulian C, Shoushtari A et al (2014) Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients. Clin Exp Rheumatol 32(6 Suppl 86):S-154–S-160Google Scholar
  36. Doria A, Sherer Y, Meroni PL et al (2005) Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 31(355–362):viiiGoogle Scholar
  37. dos Reis-Neto ET, da Silva AE, Monteiro CM et al (2013) Supervised physical exercise improves endothelial function in patients with systemic lupus erythematosus. Rheumatology 52:2187–2195PubMedCrossRefGoogle Scholar
  38. El-Magadmi M, Bodill H, Ahmad Y et al (2004) Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110:399–404PubMedCrossRefGoogle Scholar
  39. Erkan D (2006) Lupus and thrombosis. J Rheumatol 33:1715–1717PubMedGoogle Scholar
  40. Fernandes JL, Mamoni RL, Orford JL et al (2004) Increased Th1 activity in patients with coronary artery disease. Cytokine 26:131–137PubMedCrossRefGoogle Scholar
  41. Fitzgerald O, Winchester R (2009) Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 11:214PubMedPubMedCentralCrossRefGoogle Scholar
  42. Forstermann U, Munzel T (2006) Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113:1708–1714PubMedCrossRefGoogle Scholar
  43. Frech T, Walker AE, Barrett-O’Keefe Z et al (2015) Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Clin Rheumatol 34:905–913PubMedCrossRefGoogle Scholar
  44. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989–2003PubMedCrossRefGoogle Scholar
  45. Garg N, Krishan P, Syngle A (2016) Atherosclerosis in psoriatic arthritis: a multiparametric analysis using imaging technique and laboratory markers of inflammation and vascular function. Int J Angiol 25:222–228PubMedCrossRefGoogle Scholar
  46. George J, Harats D, Gilburd B et al (1999) Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99:2227–2230PubMedCrossRefGoogle Scholar
  47. Ghiadoni L, Huang Y, Magagna A et al (2001) Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. J Hypertens 19(3 Pt 2):547–551PubMedCrossRefGoogle Scholar
  48. Ghiadoni L, Versari D, Magagna A et al (2007) Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens 25:361–366PubMedCrossRefGoogle Scholar
  49. Ghiadoni L, Mosca M, Tani C et al (2008) Clinical and methodological aspects of endothelial function in patients with systemic autoimmune diseases. Clin Exp Rheumatol 26:680–687PubMedGoogle Scholar
  50. Giannattasio C, Pozzi M, Gardinali M et al (2007) Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. J Hypertens 25:793–797PubMedCrossRefGoogle Scholar
  51. Gladman DD, Ang M, Su L et al (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68:1131–1135PubMedCrossRefGoogle Scholar
  52. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al (2003) HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114:647–652PubMedCrossRefGoogle Scholar
  53. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al (2004) Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 51:447–450PubMedCrossRefGoogle Scholar
  54. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA et al (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57:287–293PubMedCrossRefGoogle Scholar
  55. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR et al (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59:1821–1824PubMedCrossRefGoogle Scholar
  56. Gresele P, Migliacci R, Vedovati MC et al (2009) Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 123:444–451PubMedCrossRefGoogle Scholar
  57. Guin A, Chatterjee Adhikari M, Chakraborty S et al (2013) Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum 43:48–54PubMedCrossRefGoogle Scholar
  58. Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876–1890PubMedCrossRefGoogle Scholar
  59. Hardie KL, Kinlay S, Hardy DB et al (1997) Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function. Austr N Z J Med 27:649–652CrossRefGoogle Scholar
  60. Hashimoto M, Akishita M, Eto M et al (1995) Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92:3431–3435PubMedCrossRefGoogle Scholar
  61. Hathaway CA, Heistad DD, Piegors DJ et al (2002) Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 90:277–283PubMedCrossRefGoogle Scholar
  62. Hawkey CJ (2001) COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 15:801–820PubMedCrossRefGoogle Scholar
  63. Hollan I, Scott H, Saatvedt K et al (2007) Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: a controlled study of biopsy specimens obtained at coronary artery surgery. Arthritis Rheum 56:2072–2079PubMedCrossRefGoogle Scholar
  64. Hollan I, Bottazzi B, Cuccovillo I et al (2010) Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res 62:378–385CrossRefGoogle Scholar
  65. Hsue PY, Scherzer R, Grunfeld C et al (2014) Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc 3:e001267PubMedPubMedCentralCrossRefGoogle Scholar
  66. Hugh J, Van Voorhees AS, Nijhawan RI et al (2014) From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 70:168–177PubMedCrossRefGoogle Scholar
  67. Hurlimann D, Forster A, Noll G et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184–2187PubMedCrossRefGoogle Scholar
  68. Jacobsson LT, Knowler WC, Pillemer S et al (1993) Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 36:1045–1053PubMedCrossRefGoogle Scholar
  69. Joannides R, Haefeli WE, Linder L et al (1995) Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91:1314–1319PubMedCrossRefGoogle Scholar
  70. Joannides R, Etienne I, Iacob M et al (2010) Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients. Transpl Int 23:1135–1143PubMedCrossRefGoogle Scholar
  71. Kerekes G, Soltész P, Szucs G et al (2011) Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 13:147–152PubMedGoogle Scholar
  72. Kiss E, Soltesz P, Der H et al (2006) Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 27:211–217PubMedCrossRefGoogle Scholar
  73. Kitas GD, Erb N (2003) Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology 42:607–613PubMedCrossRefGoogle Scholar
  74. Kosch M, Hausberg M, Suwelack B (2003) Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation 76:1516–1519PubMedCrossRefGoogle Scholar
  75. Krause D, Schleusser B, Herborn G et al (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14–21PubMedCrossRefGoogle Scholar
  76. Landewe RB, van den Borne BE, Breedveld FC et al (2000) Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355:1616–1617PubMedCrossRefGoogle Scholar
  77. Leeson P, Thorne S, Donald A et al (1997) Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart 78:22–27PubMedPubMedCentralCrossRefGoogle Scholar
  78. Li WQ, Han JL, Manson JE et al (2012) Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermat 166:811–818CrossRefGoogle Scholar
  79. Li J, Wang Y, Wang Y et al (2015) Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction. J Mol Cell Cardiol 86:62–74PubMedCrossRefGoogle Scholar
  80. Liang KP, Liang KV, Matteson EL et al (2006) Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 54:642–648PubMedPubMedCentralCrossRefGoogle Scholar
  81. Maas R, Schwedhelm E, Kahl L et al (2008) Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem 54:292–300PubMedCrossRefGoogle Scholar
  82. Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415PubMedCrossRefGoogle Scholar
  83. Manzi S, Selzer F, Sutton-Tyrrell K et al (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51–60PubMedCrossRefGoogle Scholar
  84. Maradit-Kremers H, Nicola PJ, Crowson CS et al (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732PubMedCrossRefGoogle Scholar
  85. Matsuura E, Kobayashi K, Koike T et al (2002) Autoantibody-mediated atherosclerosis. Autoimmun Rev 1:348–353PubMedCrossRefGoogle Scholar
  86. Mazzoccoli G, Notarsanto I, de Pinto GD et al (2010) Anti-tumor necrosis factor-alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Int Emerg Med 5:495–500CrossRefGoogle Scholar
  87. McMahon M, Grossman J, FitzGerald J et al (2006) Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54:2541–2549PubMedCrossRefGoogle Scholar
  88. Mercanoglu F, Erdogan D, Oflaz H et al (2004) Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. Int J Clin Pract 58:1003–1007PubMedCrossRefGoogle Scholar
  89. Meroni PL, Peyvandi F, Foco L et al (2007) Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 5:2421–2428PubMedCrossRefGoogle Scholar
  90. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–959PubMedCrossRefGoogle Scholar
  91. Murdaca G, Colombo BM, Cagnati P et al (2012) Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 224:309–317PubMedCrossRefGoogle Scholar
  92. Nadareishvili Z, Michaud K, Hallenbeck JM et al (2008) Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 59:1090–1096PubMedPubMedCentralCrossRefGoogle Scholar
  93. O’Leary DH, Bots ML (2010) Imaging of atherosclerosis: carotid intima-media thickness. Eur Heart J 31:1682–1689PubMedCrossRefGoogle Scholar
  94. Op den Buijs J, Musters M, Verrips T et al (2004) Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening. Am J Physiol Heart Circ Physiol 287:H2651–H2658PubMedCrossRefGoogle Scholar
  95. Orlandi A, Bochaton-Piallat ML, Gabbiani G et al (2006) Aging, smooth muscle cells and vascular pathobiology: implications for atherosclerosis. Atherosclerosis 188:221–230PubMedCrossRefGoogle Scholar
  96. Peretz A, Leotta DF, Sullivan JH et al (2007) Flow mediated dilation of the brachial artery: an investigation of methods requiring further standardization. BMC Cardiovasc Disord 7:11PubMedPubMedCentralCrossRefGoogle Scholar
  97. Peters MJ, van Halm VP, Voskuyl AE et al (2009) Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 61:1571–1579PubMedCrossRefGoogle Scholar
  98. Pierangeli SS, Chen PP, Raschi E et al (2008) Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 34:236–250PubMedCrossRefGoogle Scholar
  99. Pingiotti E, Cipriani P, Marrelli A et al (2007) Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci 1107:32–41PubMedCrossRefGoogle Scholar
  100. Ponthieux A, Herbeth B, Droesch S et al (2004) Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis 172:299–308PubMedCrossRefGoogle Scholar
  101. Protogerou AD, Zampeli E, Fragiadaki K et al (2011) A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 219:734–736PubMedCrossRefGoogle Scholar
  102. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116:3090–3100PubMedPubMedCentralCrossRefGoogle Scholar
  103. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939PubMedCrossRefGoogle Scholar
  104. Raitakari OT, Celermajer DS (2000) Flow-mediated dilatation. Br J Clin Pharmacol 50:397–404PubMedPubMedCentralCrossRefGoogle Scholar
  105. Rajagopalan S, Somers EC, Brook RD et al (2004) Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103:3677–3683PubMedCrossRefGoogle Scholar
  106. Ramonda R, Puato M, Punzi L et al (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine 81:421–425PubMedCrossRefGoogle Scholar
  107. Reynolds JA, Robertson AC, Bruce IN et al (2014) Improving cardiovascular outcomes in rheumatic diseases: therapeutic potential of circulating endothelial progenitor cells. Pharmacol Ther 142:231–243PubMedCrossRefGoogle Scholar
  108. Rodriguez-Rodriguez L, González-Juanatey C, García-Bermúdez M et al (2011) CCR5Delta32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther 13:R133PubMedPubMedCentralCrossRefGoogle Scholar
  109. Rollando D, Bezante GP, Sulli A et al (2010) Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol 37:1168–1173PubMedCrossRefGoogle Scholar
  110. Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399–2406PubMedCrossRefGoogle Scholar
  111. Ronda N (2012) Differential impairment of serum cholesterol efflux capacity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 64:2CrossRefGoogle Scholar
  112. Rosato E, Barbano B, Gigante A et al (2013) Erectile dysfunction, endothelium dysfunction, and microvascular damage in patients with systemic sclerosis. J Sex Med 10:1380–1388PubMedCrossRefGoogle Scholar
  113. Roustit M, Simmons GH, Baguet JP et al (2008) Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. J Rheumatol 35:1576–1583PubMedPubMedCentralGoogle Scholar
  114. Ruiz-Irastorza G, Crowther M, Branch W et al (2010) Antiphospholipid syndrome. Lancet 376:1498–1509PubMedCrossRefGoogle Scholar
  115. Schuett H, Luchtefeld M, Grothusen C et al (2009) How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 102:215–222PubMedGoogle Scholar
  116. Schurgers E, Billiau A, Matthys P (2011) Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-gamma. J Interferon Cytokine Res 31:917–926PubMedCrossRefGoogle Scholar
  117. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108PubMedCrossRefGoogle Scholar
  118. Sfikakis PP, Papamichael C, Stamatelopoulos KS et al (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56:1985–1993PubMedCrossRefGoogle Scholar
  119. Sharma SK, Rathi M, Sahoo S et al (2016) Assessment of premature atherosclerosis in systemic lupus erythematosus patients with and without nephritis. Lupus 25:525–531PubMedCrossRefGoogle Scholar
  120. Shechter M, Shechter A, Koren-Morag N et al (2014) Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease. Am J Cardiol 113:162–167PubMedCrossRefGoogle Scholar
  121. Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106PubMedCrossRefGoogle Scholar
  122. Shoenfeld Y, Gerli R, Doria A et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347PubMedCrossRefGoogle Scholar
  123. Sidiropoulos PI, Siakka P, Pagonidis K et al (2009) Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 38:6–10PubMedCrossRefGoogle Scholar
  124. Silva I, Teixeira A, Oliveira J et al (2015) Endothelial dysfunction and nailfold videocapillaroscopy pattern as predictors of digital ulcers in systemic sclerosis: a cohort study and review of the literature. Clin Rev Allergy Immunol 49:240–252PubMedCrossRefGoogle Scholar
  125. Sincer I, Kurtoğlu E, Yılmaz Çoşkun F et al (2015) Association between serum total antioxidant status and flow-mediated dilation in patients with systemic lupus erythematosus: an observational study. Anatol J Cardiol 15:913–918PubMedPubMedCentralCrossRefGoogle Scholar
  126. Skeoch S, Bruce IN (2015) Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 11:390–400PubMedCrossRefGoogle Scholar
  127. Sodergren A, Karp K, Boman K et al (2010) Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 12:R158PubMedPubMedCentralCrossRefGoogle Scholar
  128. Sokolove J, Brennan MJ, Sharpe O et al (2013) Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 65:1719–1724PubMedPubMedCentralCrossRefGoogle Scholar
  129. Soltesz P, Dér H, Kerekes G et al (2009) A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol 28:655–662PubMedCrossRefGoogle Scholar
  130. Soltesz P, Kerekes G, Dér H et al (2011) Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 10:416–425PubMedCrossRefGoogle Scholar
  131. Sorensen KE, Celermajer DS, Spiegelhalter DJ et al (1995) Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 74:247–253PubMedPubMedCentralCrossRefGoogle Scholar
  132. Stalc M, Tomsic M, Jezovnik MK et al (2011) Endothelium-dependent and independent dilation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid syndrome. Clin Exp Rheumatol 29:616–623PubMedGoogle Scholar
  133. Stamatelopoulos KS, Kitas GD, Papamichael CM et al (2009) Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 29:1702–1708PubMedCrossRefGoogle Scholar
  134. Szabo SJ, Sullivan BM, Peng SL et al (2003) Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21:713–758PubMedCrossRefGoogle Scholar
  135. Szucs G, Tímár O, Szekanecz Z et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis–relevance for prevention of vascular complications. Rheumatology 46:759–762PubMedCrossRefGoogle Scholar
  136. Tabas I, Garcia-Cardena G, Owens GK (2015) Recent insights into the cellular biology of atherosclerosis. J Cell Biol 209:13–22PubMedPubMedCentralCrossRefGoogle Scholar
  137. Taddei S, Ghiadoni L, Virdis A et al (1999) Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 100:1400–1405PubMedCrossRefGoogle Scholar
  138. Takahashi T, Asano Y, Amiya E et al (2012) Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. Mod Rheumatol 22:598–601PubMedCrossRefGoogle Scholar
  139. Takahashi T, Asano Y, Amiya E et al (2014) Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis. Mod Rheumatol 24:106–111PubMedCrossRefGoogle Scholar
  140. Takase B, Uehata A, Akima T et al (1998) Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 82(1535–1539):A7–A8Google Scholar
  141. Tincani A, Spatola L, Prati E et al (1996) The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species’ evolution. J Immunol 157:5732–5738PubMedGoogle Scholar
  142. Turesson C, McClelland RL, Christianson TJ et al (2007) Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 66:70–75PubMedCrossRefGoogle Scholar
  143. Uehata A, Lieberman EH, Gerhard MD et al (1997) Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med 2:87–92PubMedCrossRefGoogle Scholar
  144. Uyemura K, Demer LL, Castle SC et al (1996) Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97:2130–2138PubMedPubMedCentralCrossRefGoogle Scholar
  145. Vaarala O, Alfthan G, Jauhiainen M et al (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923–925PubMedCrossRefGoogle Scholar
  146. Vaarala O, Manttari M, Manninen V et al (1995) Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91:23–27PubMedCrossRefGoogle Scholar
  147. Van Doornum S, McColl G, Jenkins A et al (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48:72–80PubMedCrossRefGoogle Scholar
  148. van Halm VP, Nurmohamed MT, Twisk JW et al (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151PubMedPubMedCentralCrossRefGoogle Scholar
  149. Vanhoutte PM, Shimokawa H, Tang EH et al (2009) Endothelial dysfunction and vascular disease. Acta Physiol 196:193–222CrossRefGoogle Scholar
  150. Vaudo G, Marchesi S, Gerli R et al (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63:31–35PubMedPubMedCentralCrossRefGoogle Scholar
  151. Veselinovic MV, Zivkovic VI, Toncev S et al (2012) Carotid artery intima-media thickness and brachial artery flow-mediated vasodilatation in patients with rheumatoid arthritis. VASA 41:343–351PubMedCrossRefGoogle Scholar
  152. Wang DG, Tang XW, Fan Y et al (2014) Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis. Inflammation 37:2067–2075PubMedCrossRefGoogle Scholar
  153. Watanabe J, Charles-Schoeman C, Miao Y et al (2012) Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64:1828–1837PubMedPubMedCentralCrossRefGoogle Scholar
  154. Weisman MH, Paulus HE, Burch FX et al (2007) A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 46:1122–1125PubMedCrossRefGoogle Scholar
  155. Wong M, Jiang BY, McNeill K et al (2007) Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 36:265–269PubMedCrossRefGoogle Scholar
  156. Yilmazer B, Sahin T, Unlu BO et al (2015) Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatol Int 35:1385–1392PubMedCrossRefGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2017

Authors and Affiliations

  • Luca Moroni
    • 1
    • 2
  • Carlo Selmi
    • 3
    • 4
  • Claudio Angelini
    • 5
  • Pier Luigi Meroni
    • 4
    • 6
  1. 1.Department of Internal MedicineIRCCS Policlinico San Donato, University of MilanMilanItaly
  2. 2.Systemic Autoimmune Diseases UnitHospital ClìnicBarcelonaSpain
  3. 3.Division of Rheumatology and Clinical ImmunologyHumanitas Clinical and Research CenterMilanItaly
  4. 4.University of MilanMilanItaly
  5. 5.Division of Internal Medicine and NephrologyHumanitas Research HospitalMilanItaly
  6. 6.RheumatologyGaetano Pini HospitalMilanItaly

Personalised recommendations